The French pharmaceutical group Sanofi announced on Thursday that it was investing in a production site in France to repatriate part of the production of a cholesterol medication manufactured in Turkey since 2019.
The investment of 15 million euros on the Tours site (center) is intended to “launch production in France of Suvreza (also called Zenon in other countries)”, indicates the laboratory in a press release. A new building should be operational in 2025. “The capacity of this new unit will be around 700 million tablets per year for around twenty countries, particularly in Europe and Asia,” details the press release.
The manufacture of this drug against excess cholesterol has been carried out, since its launch in 2019, at the Sanofi site in Luleburgaz, Turkey. “The new French unit will support the growth of the product throughout the world and secure its supply,” underlines the group, in a context of political calls to regain health sovereignty in Europe.
The Tours site, which has more than 300 employees, manufactures more than 3.5 billion tablets and capsules each year, particularly for cardiovascular diseases and central nervous system disorders.